Cabrellis Pharmaceuticals Corporation

Cabrellis Pharmaceuticals Corporation (Cabrellis) is a privately held specialty pharmaceutical company that engaged in the development of innovative therapies for the treatment of lung cancers. The lead product of the company includes Calsed (amrubicin hydrochloride), a third generation synthetic anti cancer drug that possess a higher level anti-tumour activity than the conventional anthracycline without showing any cardiac toxicity. The company has initiated the phase II clinical trials of Makita LCT300W and Makita LCT400W drugs for the treatment of small-cell lung cancer. Currently, Cabrellis has been acquired by Pharmion Corporation which has obtained exclusive rights from Dainippon Sumitomo, the Japanese marketer of synthetic anthracycline Amrubicin drug to commercialize it in the North American and European market. Cabrellis is headquartered at San Diego in California, the US.

Street: 
9393 Towne Centre Drive
City: 
San Diego
Postcode: 
92121-3070
Federal State : 
United States
WebSite: 
www.cabrellis.com
Fax: 
1-858-4047120

Company Index Score

Current Index Score Historical Index Score
  • Cabrellis Pharmaceuticals Corporation currently scores 50 % in the index.
  • Cabrellis Pharmaceuticals Corporation is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Cabrellis Pharmaceuticals Corporation is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets